Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1986 Aug;88(4):827–835. doi: 10.1111/j.1476-5381.1986.tb16256.x

The effects of monoamine oxidase inhibitors on the ejaculatory response induced by 5-methoxy-N,N-dimethyltryptamine in the rat.

L Rényi
PMCID: PMC1917087  PMID: 3091132

Abstract

The ejaculatory response and other components of the 5-hydroxytryptamine (5-HT) behavioural syndrome induced by 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) (3 mg kg-1, i.p.) were studied following single and repeated treatment of rats with eight different monoamine oxidase (MAO) inhibitors. Single and repeated treatment with the 5-HT agonist 5-MeODMT, and with low doses of the potent releaser of 5-HT, p-chloroamphetamine (PCA) were also included in the study. Repeated but not single treatment with 5-MeODMT reduced strongly but reversibly the ejaculatory response and the behavioural responses. Repeated but not single treatment with the nonselective and irreversible MAO inhibitors nialamide and pargyline reduced markedly the ejaculatory response but only slightly the 5-HT behavioural responses. Repeated treatment with the irreversible MAO-B inhibitor (-)-deprenyl, with the irreversible MAO-A inhibitor, clorgyline, with the reversible MAO-A inhibitor moclobemide, and with low doses of PCA did not affect either of the responses. Repeated but not single combined treatment with clorgyline plus PCA caused an almost complete blockade of all the four responses. The selective and reversible MAO-A inhibitors (as well as 5-HT releasers) amiflamine, alpha-ethyltryptamine, and alpha-methyltryptamine reduced markedly the ejaculatory response after both single and repeated treatments. The behavioural responses were blocked only after repeated treatment. It is concluded that single and repeated treatments of rats with different MAO inhibitors do not produce a common alteration in 5-HT2 receptor functions. Repeated treatment with 5-MeODMT caused a blockade of 75-95% of the ejaculatory response and 5-HT behavioural responses.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
827

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer T., Fowler C. J., Fredriksson A., Lewander T., Magnusson O., Mohringe B., Söderberg U. Increased total activity in the rat after L-tryptophan plus the monoamine oxidase-A inhibitor amiflamine but not after L-tryptophan plus clorgyline. Br J Pharmacol. 1985 Jul;85(3):581–590. doi: 10.1111/j.1476-5381.1985.tb10552.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ashkenazi R., Finberg J. P., Youdim M. B. Behavioural hyperactivity in rats treated with selective monoamine oxidase inhibitors and LM 5008, a selective 5-hydroxytryptamine uptake blocker. Br J Pharmacol. 1983 Jul;79(3):765–770. doi: 10.1111/j.1476-5381.1983.tb10015.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ask A. L., Högberg K., Schmidt L., Kiessling H., Ross S. B. (+)-4-Dimethylamino-2,alpha-dimethylphenethylamine (FLA 336(+)), a selective inhibitor of the A form of monoamine oxidase in the rat brain. Biochem Pharmacol. 1982 Apr 1;31(7):1401–1406. doi: 10.1016/0006-2952(82)90035-1. [DOI] [PubMed] [Google Scholar]
  4. Deakin J. F., Green A. R. The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol. 1978 Oct;64(2):201–209. doi: 10.1111/j.1476-5381.1978.tb17290.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dickinson S. L., Andrews C. D., Curzon G. The effects of lesions produced by 5,7-dihydroxytryptamine on 5-hydroxytryptamine-mediated behaviour induced by amphetamine in large doses in the rat. Neuropharmacology. 1984 Apr;23(4):423–429. doi: 10.1016/0028-3908(84)90250-8. [DOI] [PubMed] [Google Scholar]
  6. Fagervall I., Ross S. B. Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. Biochem Pharmacol. 1986 Apr 15;35(8):1381–1387. doi: 10.1016/0006-2952(86)90285-6. [DOI] [PubMed] [Google Scholar]
  7. Fowler C. J., Ross S. B. Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties. Med Res Rev. 1984 Jul-Sep;4(3):323–358. doi: 10.1002/med.2610040303. [DOI] [PubMed] [Google Scholar]
  8. Fuxe K., Holmstedt B., Jonsson G. Effects of 5-methoxy-N,N-dimethyltryptamine on central monoamine neurons. Eur J Pharmacol. 1972 Jul;19(1):25–34. doi: 10.1016/0014-2999(72)90073-8. [DOI] [PubMed] [Google Scholar]
  9. Green A. R. 5-HT-mediated behavior. Animal studies. Neuropharmacology. 1984 Dec;23(12B):1521–1528. doi: 10.1016/0028-3908(84)90096-0. [DOI] [PubMed] [Google Scholar]
  10. Green A. R., Youdim M. B. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol. 1975 Nov;55(3):415–422. doi: 10.1111/j.1476-5381.1975.tb06946.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hall H., Wedel I. The effects of manipulation of presynaptic 5-HT nerve terminals on postsynaptic 5-HT1 and 5-HT2 binding sites of the rat brain. J Neural Transm. 1985;64(2):129–143. doi: 10.1007/BF01245974. [DOI] [PubMed] [Google Scholar]
  12. Jacobs B. L., Klemfuss H. Brain stem and spinal cord mediation of a serotonergic behavioral syndrome. Brain Res. 1975 Dec 19;100(2):450–457. doi: 10.1016/0006-8993(75)90500-4. [DOI] [PubMed] [Google Scholar]
  13. Johnston J. P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968 Jul;17(7):1285–1297. doi: 10.1016/0006-2952(68)90066-x. [DOI] [PubMed] [Google Scholar]
  14. Kendall D. A., Duman R., Slopis J., Enna S. J. Influence of adrenocorticotropin hormone and yohimbine on antidepressant-induced declines in rat brain neurotransmitter receptor binding and function. J Pharmacol Exp Ther. 1982 Sep;222(3):566–571. [PubMed] [Google Scholar]
  15. Knoll J., Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972;5:393–408. [PubMed] [Google Scholar]
  16. Koshikawa N., Smokcum R. W., Stephenson J. D. Is waning of a 5-hydroxytryptamine (5-HT)-mediated syndrome due to 5-HT2 receptor down-regulation? Neurosci Lett. 1985 Apr 19;55(3):279–282. doi: 10.1016/0304-3940(85)90448-3. [DOI] [PubMed] [Google Scholar]
  17. Lucki I., Frazer A. Prevention of the serotonin syndrome in rats by repeated administration of monoamine oxidase inhibitors but not tricyclic antidepressants. Psychopharmacology (Berl) 1982;77(3):205–211. doi: 10.1007/BF00464567. [DOI] [PubMed] [Google Scholar]
  18. Ogren S. O., Fuxe K., Agnati L. F., Celani M. F. Effects of antidepressant drugs on cerebral serotonin receptor mechanisms. Acta Pharmacol Toxicol (Copenh) 1985;56 (Suppl 1):105–127. doi: 10.1111/j.1600-0773.1985.tb02503.x. [DOI] [PubMed] [Google Scholar]
  19. Peroutka S. J., Snyder S. H. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science. 1980 Oct 3;210(4465):88–90. doi: 10.1126/science.6251550. [DOI] [PubMed] [Google Scholar]
  20. Rènyi L. Ejaculations induced by p-chloroamphetamine in the rat. Neuropharmacology. 1985 Aug;24(8):697–704. doi: 10.1016/0028-3908(85)90001-2. [DOI] [PubMed] [Google Scholar]
  21. Rényi L., Ross S. B. Effects of amiflamine and related compounds on the accumulation of biogenic monoamines in rat brain slices in vitro and ex vivo in relation to their behavioural effects. Acta Pharmacol Toxicol (Copenh) 1985 May;56(5):416–426. doi: 10.1111/j.1600-0773.1985.tb01312.x. [DOI] [PubMed] [Google Scholar]
  22. Rényi L. The effect of selective 5-hydroxytryptamine uptake inhibitors on 5-methoxy-N,N-dimethyltryptamine-induced ejaculation in the rat. Br J Pharmacol. 1986 Apr;87(4):639–648. doi: 10.1111/j.1476-5381.1986.tb14580.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Savage D. D., Mendels J., Frazer A. Decrease in [3H]-serotonin binding in rat brain produced by the repeated administration of either monoamine oxidase inhibitors or centrally acting serotonin agonists. Neuropharmacology. 1980 Nov;19(11):1063–1070. doi: 10.1016/0028-3908(80)90102-1. [DOI] [PubMed] [Google Scholar]
  24. Savage D. D., Mendels J., Frazer A. Monoamine oxidase inhibitors and serotonin uptake inhibitors: differential effects on [3H]serotonin binding sites in rat brain. J Pharmacol Exp Ther. 1980 Feb;212(2):259–263. [PubMed] [Google Scholar]
  25. Sills M. A., Lucki I., Frazer A. Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or mCPP. Life Sci. 1985 Jul 1;36(26):2463–2469. doi: 10.1016/0024-3205(85)90142-0. [DOI] [PubMed] [Google Scholar]
  26. Trulson M. E., Keltch G. F. Development of tolerance to repeated administration of 5-methoxy-N,N-dimethyltryptamine in rats. Eur J Pharmacol. 1985 Jan 15;108(1):33–37. doi: 10.1016/0014-2999(85)90280-8. [DOI] [PubMed] [Google Scholar]
  27. Waldmeier P. C., Delini-Stula A., Maître L. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1976;292(1):9–14. doi: 10.1007/BF00506483. [DOI] [PubMed] [Google Scholar]
  28. Willner P. Antidepressants and serotonergic neurotransmission: an integrative review. Psychopharmacology (Berl) 1985;85(4):387–404. doi: 10.1007/BF00429653. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES